At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02617 TRANSTHERA-B
Closed 05-19 16:08:19
46.600
-3.200
-6.43%
High53.800Low45.240Vol3.34M
Open47.380D1 Closing49.800Amplitude17.19%
Mkt Cap18.83BTradable Cap14.40BTotal Shares404.00M
T/O161.73MT/O Rate1.08%Tradable Shares309.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
TRANSTHERA-B Shares Drop Over 3% Following Third Fundraising via Discounted Placement This Year
Stock News  ·  11:24
TRANSTHERA-B Shares Drop Over 3% Following Third Fundraising via Discounted Placement This Year
Stock Track | TransThera-B Soars 6.12% Intraday Following Share Placement for Oncology Drug Development
Stock Track  ·  10:49
Stock Track | TransThera-B Soars 6.12% Intraday Following Share Placement for Oncology Drug Development
TransThera Sciences Seeks HK$156 Million via Share Offering
MT Newswires Live  ·  09:38
TransThera Sciences Seeks HK$156 Million via Share Offering
Stock Track | TRANSTHERA-B Plummets 5.22% in Pre-Market After Announcing Private Placement at 18% Discount
Stock Track  ·  09:37
Stock Track | TRANSTHERA-B Plummets 5.22% in Pre-Market After Announcing Private Placement at 18% Discount
TransThera Sciences places 3.84 million new H-shares at HK$40.83, raising up to HK$156.62 million
Bulletin Express  ·  06:43
TransThera Sciences places 3.84 million new H-shares at HK$40.83, raising up to HK$156.62 million
TRANSTHERA-B Announces Private Placement of Shares at a Discount to Raise Capital
Stock News  ·  06:40
TRANSTHERA-B Announces Private Placement of Shares at a Discount to Raise Capital
TransThera Sciences prices 3,836,000-share placement at HK$40.83 each
Reuters  ·  06:31
TransThera Sciences prices 3,836,000-share placement at HK$40.83 each
Transthera Sciences (Nanjing) Inc - to Place 3,836,000 New H Shares at HK$40.83 per Share
THOMSON REUTERS  ·  06:30
Transthera Sciences (Nanjing) Inc - to Place 3,836,000 New H Shares at HK$40.83 per Share
Transthera Sciences (Nanjing) Inc - Gross Proceeds Expected at HK$156.62 Mln, Net Proceeds at HK$152.13 Mln
THOMSON REUTERS  ·  06:30
Transthera Sciences (Nanjing) Inc - Gross Proceeds Expected at HK$156.62 Mln, Net Proceeds at HK$152.13 Mln
TransThera Sciences' Tinengotinib Shows Anti-tumor Efficacy in Trial
MT Newswires Live  ·  05-18 12:12
TransThera Sciences' Tinengotinib Shows Anti-tumor Efficacy in Trial
TRANSTHERA-B's Core Product Demonstrates Efficacy in Advanced Solid Tumors in Nature Communications Publication
Stock News  ·  05-17 18:48
TRANSTHERA-B's Core Product Demonstrates Efficacy in Advanced Solid Tumors in Nature Communications Publication
TransThera Highlights Promising Phase Ib/II Results for Tinengotinib in Nature Communications
Bulletin Express  ·  05-17 18:42
TransThera Highlights Promising Phase Ib/II Results for Tinengotinib in Nature Communications
Stock Track | TRANSTHERA-B Plummets 5.70% Intraday on Clinical Data Release and Sector Weakness
Stock Track  ·  05-13
Stock Track | TRANSTHERA-B Plummets 5.70% Intraday on Clinical Data Release and Sector Weakness
TransThera Sciences Issues 5.09 Million H Shares in April Placement, Expanding Total Share Capital to 404.08 Million
Bulletin Express  ·  05-06
TransThera Sciences Issues 5.09 Million H Shares in April Placement, Expanding Total Share Capital to 404.08 Million
TRANSTHERA-B's Third Fundraising in Under a Year: 18% Discounted Placement Raises HK$290 Million While Prior Funds Remain Unused
Deep News  ·  04-30
TRANSTHERA-B's Third Fundraising in Under a Year: 18% Discounted Placement Raises HK$290 Million While Prior Funds Remain Unused
TransThera聚焦创新药研发，2025年净亏损约2.96亿元，核心管线获监管突破
Bulletin Express  ·  04-23
TransThera聚焦创新药研发，2025年净亏损约2.96亿元，核心管线获监管突破
TransThera unveils inaugural ESG report: Tinengotinib NDA accepted, 2025 greenhouse-gas emissions at 728.89 t
Bulletin Express  ·  04-23
TransThera unveils inaugural ESG report: Tinengotinib NDA accepted, 2025 greenhouse-gas emissions at 728.89 t
Transthera Sciences publishes 2025 annual report
Reuters  ·  04-23
Transthera Sciences publishes 2025 annual report
TransThera Completes HK$290.00 Million H-Share Placement at HK$57.03 Each, Expanding Free Float by 1.65%
Bulletin Express  ·  04-21
TransThera Completes HK$290.00 Million H-Share Placement at HK$57.03 Each, Expanding Free Float by 1.65%
TRANSTHERA-B Completes Placement of 5.085 Million Shares, Raising Approximately HK$282 Million Net
Stock News  ·  04-21
TRANSTHERA-B Completes Placement of 5.085 Million Shares, Raising Approximately HK$282 Million Net

Introduction

Company Name.
TRANSTHERA-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
TransThera Sciences (Nanjing) Inc is a China-based biopharmaceutical company principally focusing on discovering and developing innovative small molecule therapies for oncology, inflammatory and cardiometabolic diseases. The Company's core product Tinengotinib is a registrational clinical stage, internally discovered and developed, MTK inhibitor indicated for certain relapsed or refractory, drug-resistant solid tumors. The Company's oncology pipeline includes TT-00973 (against AXL), TT-01488 (for hematologic malignancies), TT-01688 (for inflammatory diseases) and TT-00920 (for chronic heart failure). The products are capable of being efficacious in a broad range of cancer types (including prostate cancer, HCC, breast cancer, and BTC). It is also applied to cure hepatocellular carcinoma, breast cancer, biliary tract cancer and Pan-FGFR solid tumor.
Issue price:
--